Coagulation factor V G allele and HR2 haplotype: Factor V activity, activated protein C resistance and risk of venous thrombosis

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 1, 2003, Pages 49-56

  Kostka, Heike ^a   Schwarz, Thomas ^a   Schellong, Sebastian ^a   Mix, Cornelia ^a   Kuhlisch, Eberhard ^b   Temelkova Kurktschiev, Theodora ^b   Henkel, Elena ^b   Köhler, Carsta ^b   Gehrisch, Siegmund ^a   Siegert, Gabriele ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Activated protein C response; Factor V activity; G allele; HR2 haplotype; Thrombosis risk

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; NUCLEOTIDE;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ALLELE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENE FREQUENCY; GUANINE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 12244252264     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200301000-00009     Document Type: Article

References (36)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci U S A 1993; 90:1004-1008.
2. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82:1989-1993.
3. Koster T, Rosendaal FR, De Ronde F, Briet E, Vadenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342:1503-1506.
4. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-521.
5. Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5:51-57.
6. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Driven RJ, De Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
7. Dahlback B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999; 25:273-289.
8. Siegert G, Gehrisch S, Runge E, Schwarz T, Schimmanck S, Schellong S, et al. Comparison of the APC response in various test systems with the result of factor V genotyping. Haemostaseologie 1997; 17:170-175.
9. Zöller B, Svensson B, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94:2521-2524.
10. Kane WH, Devore-Carter D, Ortel TL. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. Biochemistry 1990; 29:6762-6768.
11. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269:18735-18738.
12. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of the protein S in the APC-mediated inactivation of factor VIII: influence of the factor V R506Q mutation. Thromb Haemost 1996; 76:208-214.
13. Thorelli E, Kaufman PJ, Dahlback B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273:16140-16145.
14. Lunghi B, Iacoviello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75:45-48.
15. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90:1552-1557.
16. Castoldi E, Rosing J, Girelli D, Hoekema L, Lunghi B, Mingozzi F, et al. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83:362-365.
17. Alhenc-Gelas M, Nicaud V, GandrilleS, van Dreden P, Amiral J, Aubry ML, et al. The factor V gene A4070G mutation and risk of venous thrombosis. Thromb Haemost 1999; 81:193-197.
18. Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94:3062-3066.
19. Kostka H, Siegert G, Schwarz T, Gehrisch S, Kuhlisch E, Schellong S, Jaross W. Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients. Thromb Res 2000; 99:539-547.
20. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83:577-582.
21. Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000; 83:204-208.
22. Siegert G, Kostka H, Kuhlisch E, Schwarz T, Schellong S, Jaross W. Investigation of genotype-dependent differences in factor V activity as well as response to activated protein C by application of different methods. Blood Coagul Fibrinolysis 2001; 12:683-690.
23. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84:4846-4850.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells [Letter]. Nucleic Acids Res 1988; 16:1215.
25. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
26. Siegert G, Kostka H, Gehrisch S, Schwarz T, Schellong SM, Jaross W. Method-dependent influence of certain polymorphism in the factor V B-domain on the response to activated protein C. Blood Coagul Fibrinolysis 2000; 11:519-527.
27. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93:1271-1276.
28. Cox MJ, Rees DC, Martinson JJ, Clegg JB. Evidence for single origin of factor V Leiden. Br J Haematol 1996; 92:1022-1025.
29. Zoller B, Hillarp A, Dahlback B. Activated protein C resistance caused by a common factor V mutation has a single origin. Thromb Res 1997; 85:237-243.
30. Le W, Yu JD, Lu L, Tao R, You B, Cai X, et al. Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population. Clin Genet 2000; 57:296-303.
31. Hoekema L, Nicolaes GA, Hemker HC, Tans G, Rosing J. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry 1997; 36:3331-3335.
32. Nicolaes GA, Villoutreix BO, Dahlback B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry 1999; 38:13584-13591.
33. Pecheniuk NM, Morris CP, Walsh TP, Marsh NA. The factor HR2 haplotype: prevalence and association of the A4070G and A6755G polymorphisms. Blood Coagul Fibrinolysis 2001; 21:201-206.
34. Castaman G, Lunghi B, Missiaglia, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506GIn (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol 1997; 99:257-261.
35. Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000; 20:1382-1386.
36. Margalione M, Bossone A, Coalizzo D, D'Andrea G, Brancaccio V, Ciampa A, et al.FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 2002; 87:32-36.